Abstract
The present disclosure relates to engineering bacteria and methods for promoting barrier function in skin and mucosal surfaces. In particular, the disclosure is related to engineering bacterium to produce a delta hemolysin (delta toxin) peptide and methods of using the engineered bacteria or the delta hemolysin peptide for improving or maintaining gut health, regulating glucose metabolism, maintaining intestinal integrity, decreasing inflammation, modulating wound healing and tissue regeneration, and treating or preventing a disease or disorder.
Full Text
What is claimed is:
The present disclosure relates to engineering bacteria and methods for promoting barrier function in skin and mucosal surfaces. In particular, the disclosure is related to engineering bacterium to produce a delta hemolysin (delta toxin) peptide and methods of using the engineered bacteria or the delta hemolysin peptide for improving or maintaining gut health, regulating glucose metabolism, maintaining intestinal integrity, decreasing inflammation, modulating wound healing and tissue regeneration, and treating or preventing a disease or disorder.
Timeline
Filed
04/15/2026Published
07/30/2026Granted
Not AvailableIPC Codes(10)
C12N 15/70:Vectors or expression systems specially adapted for E. coli
A61K 35/00:Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K 38/00:Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00)